Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viridian Therapeutics, Inc.\DE (VRDN) Shares Issued (2016 - 2025)

Viridian Therapeutics, Inc.\DE (VRDN) has 12 years of Shares Issued data on record, last reported at $8.4 million in Q4 2025.

  • For Q4 2025, Shares Issued rose 123.29% year-over-year to $8.4 million; the TTM value through Dec 2025 reached $12.1 million, changed N/A, while the annual FY2025 figure was $12.1 million, N/A changed from the prior year.
  • Shares Issued reached $8.4 million in Q4 2025 per VRDN's latest filing, up from $2.0 million in the prior quarter.
  • Across five years, Shares Issued topped out at $109.8 million in Q4 2023 and bottomed at -$36.3 million in Q4 2024.
  • Average Shares Issued over 5 years is $13.2 million, with a median of $2.0 million recorded in 2025.
  • Peak YoY movement for Shares Issued: skyrocketed 249330.77% in 2021, then plummeted 135.24% in 2023.
  • A 5-year view of Shares Issued shows it stood at $32.4 million in 2021, then crashed by 94.28% to $1.9 million in 2022, then soared by 5822.76% to $109.8 million in 2023, then tumbled by 133.03% to -$36.3 million in 2024, then soared by 123.29% to $8.4 million in 2025.
  • Per Business Quant database, its latest 3 readings for Shares Issued were $8.4 million in Q4 2025, $2.0 million in Q3 2025, and $1.6 million in Q1 2025.